BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
Herbert Loong, MD, The Chinese University of Hong Kong, Hong Kong, China, discusses results from the SOHO-01 trial. In this phase 1/2 trial, researchers assessed the efficacy of BAY 2927088, a HER2 tyrosine kinase inhibitor, among patients with HER2-mutated non-small cell lung cancer (NSCLC). Consistent with prior findings, BAY 2927088 demonstrated promising efficacy and safety.
These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
Source:
Loong H, Li L, Wu L, et al. SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but naïve to HER2-targeted therapy or had not received any treatment for advanced disease. Presented at 2025 ASCO Annual Meeting. May 30-June 3, 2025; Chicago, IL. Abstract 8504
